113 related articles for article (PubMed ID: 25108120)
1. The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-specific survival in pancreatic ductal adenocarcinoma.
Kimura T; Kitada S; Uramoto H; Zhi L; Kawatsu Y; Takeda T; Horie S; Nabeshima A; Noguchi H; Sasaguri Y; Izumi H; Kohno K; Yamada S
Histol Histopathol; 2015 Feb; 30(2):193-204. PubMed ID: 25108120
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial transcription factor a worsens the clinical course of patients with pancreatic cancer through inhibition of apoptosis of cancer cells.
Yamauchi M; Nakayama Y; Minagawa N; Torigoe T; Shibao K; Yamaguchi K
Pancreas; 2014 Apr; 43(3):405-10. PubMed ID: 24622070
[TBL] [Abstract][Full Text] [Related]
3. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma.
Zhou L; Lu J; Liang ZY; Zhou WX; Yuan D; Li BQ; You L; Guo JC; Zhao YP
J Surg Oncol; 2018 Dec; 118(7):1115-1121. PubMed ID: 30261114
[TBL] [Abstract][Full Text] [Related]
4. Survivin expression and serum levels in pancreatic cancer.
Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of mitochondrial transcription factor A expression in patients with colorectal cancer.
Nakayama Y; Yamauchi M; Minagawa N; Torigoe T; Izumi H; Kohno K; Yamaguchi K
Oncol Rep; 2012 May; 27(5):1325-30. PubMed ID: 22266811
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Mitochondrial Transcription Factor A Expression in Patients with Right- or Left-sided Colorectal Cancer.
Katsuki T; Nakayama Y; Akiyama M; Sawatsubashi Y; Nagata J; Minagawa N; Torigoe T; Izumi H; Kohono K; Hirata K
Anticancer Res; 2018 Jan; 38(1):569-575. PubMed ID: 29277826
[TBL] [Abstract][Full Text] [Related]
7. The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma.
Takeda T; Izumi H; Kitada S; Uramoto H; Tasaki T; Zhi L; Guo X; Kawatsu Y; Kimura T; Horie S; Nabeshima A; Noguchi H; Wang KY; Sasaguri Y; Kohno K; Yamada S
Tumour Biol; 2014 Oct; 35(10):10555-69. PubMed ID: 25060178
[TBL] [Abstract][Full Text] [Related]
8. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis.
Sun HC; Qiu ZJ; Liu J; Sun J; Jiang T; Huang KJ; Yao M; Huang C
Int J Oncol; 2007 Jun; 30(6):1359-67. PubMed ID: 17487356
[TBL] [Abstract][Full Text] [Related]
9. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients.
Tonini G; Vincenzi B; Santini D; Scarpa S; Vasaturo T; Malacrino C; Coppola R; Magistrelli P; Borzomati D; Baldi A; Antinori A; Caricato M; Nuzzo G; Picciocchi A
Br J Cancer; 2005 Jun; 92(12):2225-32. PubMed ID: 15928668
[TBL] [Abstract][Full Text] [Related]
10. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
11. BIRC7 and KLF4 expression in benign and malignant lesions of pancreas and their clinicopathological significance.
Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):437-444. PubMed ID: 27802195
[TBL] [Abstract][Full Text] [Related]
12. Decreased circadian component Bmal1 predicts tumor progression and poor prognosis in human pancreatic ductal adenocarcinoma.
Li W; Liu L; Liu D; Jin S; Yang Y; Tang W; Gong L
Biochem Biophys Res Commun; 2016 Mar; 472(1):156-62. PubMed ID: 26915801
[TBL] [Abstract][Full Text] [Related]
13. The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma.
Sagol O; Yavuzsen T; Oztop I; Ulukus C; Ylmaz U; Alakavuklar M; Karademir S; Obuz F; Astarcoğlu H; Astarcoglu I
Pancreas; 2005 May; 30(4):343-8. PubMed ID: 15841045
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer.
Kurita T; Izumi H; Kagami S; Kawagoe T; Toki N; Matsuura Y; Hachisuga T; Kohno K
Cancer Sci; 2012 Feb; 103(2):239-444. PubMed ID: 22098591
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX.
Yoshida Y; Hasegawa J; Nezu R; Kim YK; Hirota M; Kawano K; Izumi H; Kohno K
Cancer Sci; 2011 Mar; 102(3):578-82. PubMed ID: 21205083
[TBL] [Abstract][Full Text] [Related]
16. Expression of mitochondrial transcription factor A in endometrial carcinomas: clinicopathologic correlations and prognostic significance.
Toki N; Kagami S; Kurita T; Kawagoe T; Matsuura Y; Hachisuga T; Matsuyama A; Hashimoto H; Izumi H; Kohno K
Virchows Arch; 2010 Apr; 456(4):387-93. PubMed ID: 20232213
[TBL] [Abstract][Full Text] [Related]
17. Human mitochondrial transcription factor A functions in both nuclei and mitochondria and regulates cancer cell growth.
Han B; Izumi H; Yasuniwa Y; Akiyama M; Yamaguchi T; Fujimoto N; Matsumoto T; Wu B; Tanimoto A; Sasaguri Y; Kohno K
Biochem Biophys Res Commun; 2011 Apr; 408(1):45-51. PubMed ID: 21453679
[TBL] [Abstract][Full Text] [Related]
18. Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma.
Bhanot U; Heydrich R; Möller P; Hasel C
Am J Surg Pathol; 2006 Jun; 30(6):754-9. PubMed ID: 16723855
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of Smac and survivin expression in breast cancer patients treated with anthracycline‑based neoadjuvant chemotherapy.
Zhao YC; Wang Y; Ni XJ; Li Y; Wang XM; Zhu YY; Luo CY
Mol Med Rep; 2014 Feb; 9(2):614-20. PubMed ID: 24317109
[TBL] [Abstract][Full Text] [Related]
20. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
